Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
December 2018
-
Key Release
Novartis announces new CEO of Oncology Business Unit
Susanne Schaffert, Ph.D., President, AAA, an established Novartis executive, named new CEO, Novartis Oncology Basel, December 20, 2018 - Novartis announced today that Susanne Schaffert, Ph.D.,… -
Media Release
Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises
Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have… -
Media Release
Alcon Announces Acquisition of Tear Film Innovations, Inc.
Acquisition further expands Alcon's portfolio of comprehensive solutions for patients with dry eye Tear Film's iLux® Device offers innovative, customizable treatment for Meibomian Gland… -
Media Release
Novartis receives European Commission approval for self-administration of Xolair® across all indications
The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe[1] Xolair® (omalizumab) prefilled… -
Story Discovery
Women in Science: Susanne Schaffert
Susanne Schaffert, President of Advanced Accelerator Applications, describes her career in science.
-
Story
Bringing real change to people
An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.
-
Media Release
Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
reSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two… -
Story Patient Perspectives
The changing landscape of cancer treatment
-
Media Release
Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine… -
Story Access to Healthcare
Improving lives through community-based care
Bringing healthcare closer to where people live, work and shop can effectively tackle hypertension – the most deadly noncommunicable disease.
-
Media Release
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor… -
Story Discovery
From patient to patient advocate: how a cancer diagnosis fueled a new career path
Elyse Spatz Caplan’s cancer diagnosis impacted her life in more ways than 1